CPX-351对比7+3方案治疗老年高危或继发性急性髓系白血病的5年随访结果
这项随机、开放标签、多中心3期试验纳入309例60-75岁新诊断高危或继发性急性髓系白血病患者,随机接受CPX-351或7+3方案诱导化疗。
要点
- 5年OS率CPX-351组18%(95%CI 12-25%),7+3组8%(95%CI 4-13%)。
- 两组最常见死因均为疾病进展,治疗相关死亡各约5%。
核心结论
- 经过5年随访,CPX-351对比7+3方案的总生存获益得以维持,支持CPX-351可为60-75岁新诊断高危或继发性急性髓系白血病患者带来长期缓解和生存改善。
研究设计与样本
- 随机、开放标签、多中心3期试验,在美国和加拿大39个学术和区域癌症中心开展。
- 纳入309例60-75岁、符合WHO 2008标准病理诊断、未接受过诱导治疗、ECOG体能状态0-2的新诊断高危或继发性急性髓系白血病患者,按1:1随机分组。
- CPX-351组153例,7+3组156例;主要终点为所有随机化患者的总生存期。
主要发现
- 5年总生存率CPX-351组18%(95%CI 12-25%),7+3组8%(95%CI 4-13%)。
- 最常见死因均为疾病进展:CPX-351组124例死亡中70例(56%),7+3组140例死亡中74例(53%)。
- 治疗相关死亡:CPX-351组124例中6例(5%),7+3组140例中7例(5%)。
关键数值与推荐
- CPX-351诱导方案:100 units/m2,90分钟静脉输注,第1、3、5天;第二疗程诱导第1、3天给药。
- 标准7+3方案:阿糖胞苷100 mg/m2/天持续静脉输注7天,柔红霉素60 mg/m2静脉注射第1、2、3天;第二诱导为5+2方案。
- 巩固治疗:CPX-351 65 units/m2 90分钟输注第1、3天;或5+2化疗,最多两个周期。
临床怎么用
- 对于60-75岁新诊断高危或继发性急性髓系白血病患者,CPX-351较7+3方案可带来长期总生存获益,支持其作为该人群的诱导治疗选择。
局限性
- 长期随访仅收集死亡数据,未额外收集不良事件。
- 研究仅纳入60-75岁、ECOG 0-2的高危或继发性急性髓系白血病患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Daunorubicin and cytarabine are used as standard induction chemotherapy for patients with acute myeloid leukaemia. CPX-351 is a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio. Primary analysis of the phase 3 trial in adults aged 60-75 years with newly diagnosed high-risk or secondary acute myeloid leukaemia provided support for approval of CPX-351 by the US Food and Drug Administration and European Medicines Agency. We describe the prospectively planned final 5-year follow-up results. METHODS: This randomised, open-label, multicentre, phase 3 trial was done across 39 academic and regional cancer centres in the USA and Canada. Eligible patients were aged 60-75 years and had a pathological diagnosis of acute myeloid leukaemia according to WHO 2008 criteria, no previous induction therapy for acute myeloid leukaemia, and an Eastern Cooperative Oncology Group performance status of 0-2. Patients were randomly assigned 1:1 (stratified by age and acute myeloid leukaemia subtype) to receive up to two induction cycles of CPX-351 (100 units/m2 administered as a 90-min intravenous infusion on days 1, 3, and 5; on days 1 and 3 for the second induction) or standard chemotherapy (cytarabine 100 mg/m2 per day continuous intravenous infusion for 7 days plus intravenous daunorubicin 60 mg/m2 on days 1, 2, and 3 [7+3]; cytarabine for 5 days and daunorubicin on days 1 and 2 for the second induction [5+2]). Patients with complete remission or complete remission with incomplete neutrophil or platelet recovery could receive up to tw cycles of consolidation therapy with CPX-351 (65 units/m2 90-min infusion on days 1 and 3) or chemotherapy (5+2, same dosage as in the second induction cycle). The primary outcome was overall survival analysed in all randomly assigned patients. No additional adverse events were collected with long-term follow-up, except data for deaths. This trial is registered with ClinicalTrials.gov, NCT01696084, and is complete. FINDINGS: Between Dec 20, 2012, and Nov 11, 2014, 309 patients with newly diagnosed high-risk or secondary acute myeloid leukaemia were enrolled and randomly assigned to receive CPX-351 (153 patients) or 7+3 (156 patients). At a median follow-up of 60·91 months (IQR 60·06-62·98) in the CPX-351 group and 59·93 months (59·73-60·50) in the 7+3 group, median overall survival was 9·33 months (95% CI 6·37-11·86) with CPX-351 and 5·95 months (4·99-7·75) with 7+3 (HR 0·70, 95% CI 0·55-0·91). 5-year overall survival was 18% (95% CI 12-25%) in the CPX-351 group and 8% (4-13%) in the 7+3 group. The most common cause of death in both groups was progressive leukaemia (70 [56%] of 124 deaths in the CPX-351 group and 74 [53%] of 140 deaths in the 7+3 group). Six (5%) of 124 deaths in the CPX-351 group and seven (5%) of 140 deaths in the 7+3 group were considered related to study treatment. INTERPRETATION: After 5 years of follow-up, the improved overall survival with CPX-351 versus 7+3 was maintained, which supports the previous evidence that CPX-351 can contribute to long-term remission and improved overall survival in patients aged 60-75 years with newly diagnosed high-risk or secondary acute myeloid leukaemia. FUNDING: Jazz Pharmaceuticals.
引用
- Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021. PMID: 34171279. doi:10.1016/S2352-3026(21)00134-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。